SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
GAITHERSBURG, Md., April 13, 2016 -- Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that Bill Enright, Chief Executive Officer, will participate in a vaccine development panel at the Annual Regional Biotech Forum. The panel will take place in Gaithersburg, MD on April 19, 2016 at 9:30 AM ET.
The panel, titled “Advancements in Vaccine Development,” will be moderated by Dr. Ripley Ballou, Vice President & Head of Global Vaccines at GlaxoSmithKline. Mr. Enright will discuss Altimmune’s innovative approaches to vaccine development and how vaccine development is leading the way in the regional push to become the third largest biotech cluster in the United States.
About Altimmune
Altimmune is a clinical stage immunotherapeutic company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The Company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines. Using these technologies, Altimmune has developed three novel clinical stage product candidates that potentially represent an entirely new approach to harnessing the immune system.
The Company’s most advanced product candidate, NasoVAX, is a Phase 2-ready intranasally-delivered recombinant influenza vaccine offering broad and rapid protection with potential for significant advantages over traditional flu vaccines. The second most advanced product candidate, HepTcell, is being tested as an immunotherapy for patients chronically infected with hepatitis B and has the potential to provide a functional cure. With the support of the U.S. Biomedical Advanced Research and Development Authority, or BARDA, the Company is developing a third product candidate, NasoShield, a first-in-class anthrax vaccine designed to provide rapid, stable protection after one intranasal administration. The Company intends to leverage the RespirVec and Densigen platforms to develop additional product candidates for a variety of indications.
Contacts: Bill Enright President and CEO Phone: 240-654-1450 Email: [email protected] Investor Relations Stephanie Carrington ICR, Inc. Phone: 646-277-1282 Email: [email protected]
